Celldex drops as Pfizer dumps rindopepimut
This article was originally published in Scrip
Celldex Therapeutics suffered a sharp drop in its share price, wiping almost $40 million off its value to $113 million, following news that Pfizer is terminating their collaboration over rindopepimut, an investigational brain cancer vaccine that was the subject of a $440 million deal signed in 2008, which included a $40 million upfront payment.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.